[HTML][HTML] Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
E Guttman-Yassky, R Bissonnette, B Ungar… - Journal of Allergy and …, 2019 - Elsevier
Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with
atopic/allergic diseases. Objective This placebo-controlled, double-blind trial
(NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on
molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers
of patients with moderate-to-severe atopic dermatitis (AD). Methods Skin biopsy specimens …
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with
atopic/allergic diseases. Objective This placebo-controlled, double-blind trial
(NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on
molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers
of patients with moderate-to-severe atopic dermatitis (AD). Methods Skin biopsy specimens …
